Alcon
Company History
Alcon History: Founding, Growth & Key Milestones
Founded 1945
When was Alcon founded?
Alcon was founded in 1945 by Robert Alexander and William Conner, making it 81 years old.
- Founded
- 1945
- Founders
- Robert Alexander and William Conner
- Milestones documented
- 12 (1945–2024)
- Current CEO
- David J. Endicott
- Acquisitions
- 3
| Year | Event |
|---|---|
| 1945 | Founding in Fort Worth, Texas |
| 1953 | Invention of the Drop-Tainer Bottle |
| 1971 | Initial Public Offering on the NYSE |
| 1977 | Acquisition by Nestlé S.A. |
| 1994 | FDA Approval of AcrySof Intraocular Lens |
| 2000 | Launch of Systane Lubricant Eye Drops |
| 2008 | Novartis Acquires Initial 25% Stake from Nestlé |
| 2011 | Novartis Completes Full Takeover and Merges CIBA Vision |
| 2013 | Commercialization of Centurion Vision System |
| 2019 | Historic $28 Billion Spin-Off from Novartis |
| 2022 | Acquisitions of Aerie Pharmaceuticals and Ivantis |
| 2024 | Net Sales Reach Record $9.82 Billion |
- Who founded Alcon?
- Alcon was founded by Robert Alexander and William Conner.
- When did Alcon start?
- Alcon was founded in 1945.
- How old is Alcon?
- Alcon is 81 years old as of 2026.
Founding Story
Alcon's commercial genesis began with a shared vision between two Texas pharmacists who believed eye care deserved its own specialized manufacturing science. By merging the first syllables of their surnames—Robert Alexander and William Conner—they registered 'Alcon Laboratories' in 1945. While conventional drug manufacturers viewed ophthalmology as a tiny niche market secondary to systemic medications, Alexander and Conner focused exclusively on the human eye's delicate physiology. They discovered that ophthalmic solutions required precise pH balancing and isotonic stabilization to prevent severe stinging and tissue damage upon instillation. Working out of their small Fort Worth laboratory, they pioneered pre-mixed balanced salt solutions (BSS), which soon became the universal standard for irrigating eyes during cataract extractions. This unwavering devotion to surgical ophthalmology laid the groundwork for decades of biomaterial breakthroughs, transforming an independent Fort Worth pharmacy into an enterprise that would eventually touch more than 260 million patients across 140 countries annually.
Founders
Robert Alexander
Robert Alexander was an American pharmacist who co-founded Alcon Laboratories in Fort Worth, Texas in 1945 alongside William Conner. The duo combined their names (Alexander and Conner) to create the brand 'Alcon'. Alexander focused on sterile pharmaceutical compounding, recognizing that ophthalmologists lacked reliable, pre-mixed sterile solutions for eye surgery and infection treatment.
William Conner
William Conner was an American pharmacist and entrepreneur who co-founded Alcon Laboratories in 1945. Conner led early commercial operations, marketing vacuum-sealed saline and specialized eye medications directly to Dallas-Fort Worth physicians before expanding distribution nationwide across United States hospital clinics.
Key Milestones
Founding in Fort Worth, Texas
Pharmacists Robert Alexander and William Conner open a neighborhood pharmacy and begin formulating sterile ophthalmic preparations.
Invention of the Drop-Tainer Bottle
Alcon patents the first plastic squeeze bottle designed to dispense sterile eye drops drop-by-drop without air contamination.
Initial Public Offering on the NYSE
Alcon lists its common shares publicly on the New York Stock Exchange, raising capital to build international manufacturing facilities.
Acquisition by Nestlé S.A.
Swiss consumer and nutrition titan Nestlé acquires Alcon for approximately $280 million, providing extensive global resources.
FDA Approval of AcrySof Intraocular Lens
Alcon introduces AcrySof, the world's first foldable acrylic biomaterial intraocular lens for modern cataract surgery.
Launch of Systane Lubricant Eye Drops
Alcon commercializes the Systane dry eye franchise, utilizing advanced polymers to restore the eye's natural tear film.
Novartis Acquires Initial 25% Stake from Nestlé
Swiss healthcare giant Novartis initiates a multi-stage buyout of Alcon, purchasing an initial 25% equity interest.
Novartis Completes Full Takeover and Merges CIBA Vision
Novartis buys out remaining shares and merges its CIBA Vision contact lens unit into Alcon Laboratories.
Commercialization of Centurion Vision System
Alcon launches its next-generation Centurion phacoemulsification console with Active Fluidics technology.
Historic $28 Billion Spin-Off from Novartis
Novartis spins off 100% of Alcon shares to existing shareholders; Alcon lists independently on the SIX Swiss Exchange and NYSE.
Acquisitions of Aerie Pharmaceuticals and Ivantis
Alcon acquires Aerie ($770M) and Ivantis ($475M) to expand into prescription glaucoma drugs and MIGS microstents.
Net Sales Reach Record $9.82 Billion
Alcon reports record financial results driven by double-digit growth in Clareon IOLs and water-gradient contact lenses.
Major Acquisitions
Aerie Pharmaceuticals
2022Ivantis, Inc.
2022STAAR Surgical (Strategic Collaboration & Lens Assets)
2020Keep researching Alcon
Alcon Company History FAQ
How did Alcon start in Fort Worth, Texas?
Alcon was founded in 1945 as a small retail compounding pharmacy by pharmacists Robert Alexander and William Conner. Seeing local eye doctors struggle with unsterile solutions, they began formulating specialized, sterile ophthalmic drops and invented the Drop-Tainer plastic bottle in 1953.
Why did Nestlé sell Alcon to Novartis?
Nestlé owned Alcon from 1977 until 2010, earning an extraordinary return on its original $280 million investment. Nestlé decided to divest Alcon in stages to Novartis for $51 billion between 2008 and 2011 to refocus its corporate capital purely on consumer food, beverage, and nutritional health.
When did Alcon become an independent company again?
Alcon became an independent publicly traded corporation on April 9, 2019, following a 100% tax-free spin-off from Novartis. It listed simultaneously on the SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol ALC.
What was Alcon's most significant surgical breakthrough?
In 1994, Alcon introduced the AcrySof intraocular lens, the world's first foldable acrylic biocompatible lens. This allowed eye surgeons to insert an artificial lens through an incision smaller than 3 millimeters, revolutionizing outpatient cataract surgery.
Explore Alcon
Core profile pages, founders and related research hubs for this company.